Chapter

Gene Therapy for Leukemia and Lymphoma

12/2009; DOI:10.1007/978-1-4419-5698-9_5 pp.81-89

ABSTRACT With the advancement of knowledge in immunology and virology, technological improvement in the transduction efficiency of
existing viral vectors, and the development of new viral vectors in the past two decades, gene therapy targeting diseases
at a molecular level has emerged as an exciting and promising strategy for treating hematolymphoid malignancies. Gene therapy
is aimed to correct disease processes by introducing a functional gene into target cells to restore or modify cellular functions.
Unlike conventional therapies for treating cancers, gene therapy, in theory, could deliver precise, malignancy-specific treatment
with minimal side effects on normal cells and biological processes. For many patients with hematolymphoid malignancies who
cannot benefit from the therapies available today, gene therapy may hold the promise of future treatment.

0 0
 · 
0 Bookmarks
 · 
18 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

biological processes
 
cancers
 
cellular functions
 
correct disease processes
 
minimal side effects
 
molecular level
 
new viral vectors
 
precise
 
promising strategy
 
target cells
 
technological improvement
 
therapies available
 
transduction efficiency
 
two decades
 
viral vectors
 
virology
 

Xiaopei Huang